Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer
Authors:
- Chemotherapy Study Group of Head and Neck CancerCCChemotherapy Study Group of Head and Neck Cancer
- M TsukudaMTM Tsukuda
Open Access
- 27 September 2005
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 93 (8) , 884-889
Abstract
The purpose of this study was to determine the feasible adjuvant therapy administration schedule of S-1 for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). Patients receiving definitive treatments were randomly assigned to either arm A (51 cases) receiving oral S-1 of 2-week administration followed by 1-week rest for 6 months, or arm B receiving S-1 of 4-week administration followed by 2-week rest for 6 months. Planned treatment was given in 40% of patients in arm A and 29% in arm B. The cumulative rates of the relative total administration dose of S-1 at 100% were 54.9% (95% CI: 40.1-69.7%) in arm A and 34.3% (95% CI: 21.1-47.4%) in arm B, respectively (P=0.054). Adverse events were recorded in 41 patients (82.0%) in arm A and 48 patients (94.1%) in arm B (P=0.060). The incidences of diarrhoea (10 vs 28%; P<0.05) and skin toxicities (18 vs 37%; P<0.05) were significantly higher in arm B. One-year disease-free survival was similar in both arms: arm A 81.2% (95% CI: 70.0-92.4%); arm B 77.0% (95% CI: 65.0-89.0%). The schedule of 2-week administration followed by 1-week rest seems to be more feasible for oral 6-month administration of S-1 in adjuvant chemotherapy of locoregionally advanced SCCHN.Keywords
This publication has 27 references indexed in Scilit:
- Postoperative Adjuvant Therapy With Tamoxifen, Tegafur Plus Uracil, or Both in Women With Node-Negative Breast Cancer: A Pooled Analysis of Six Randomized Controlled TrialsJournal of Clinical Oncology, 2005
- Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experienceAnnals of Oncology, 2004
- Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancerGastric Cancer, 2004
- The Expanding Role of Systemic Therapy in Head and Neck CancerJournal of Clinical Oncology, 2004
- The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumorsAnti-Cancer Drugs, 2004
- Docetaxel, cisplatin, and 5‐fluorouracil‐based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neckCancer, 2003
- Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric CancerOncology, 2000
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patientsEuropean Journal of Cancer, 1998
- Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnti-Cancer Drugs, 1996